Background {#Sec1}
==========

Lung cancer is the leading cause of cancer-related death in China \[[@CR1]\]. The standard treatment of lung cancer, especially non-small cell lung cancer (NSCLC) comprises platinum-based chemotherapy and driver gene-based targeted therapy, which resulted in extended survival and increased the quality of life in NSCLC patients \[[@CR2]--[@CR7]\]. However, drug resistance is a major challenge in most patients \[[@CR8]\]. The median survival time in advanced NSCLC is no more than 2 years because of limited treatments available excluding chemotherapy and targeted therapy \[[@CR9], [@CR10]\].

Blockade of immune checkpoints in cancer with monoclonal antibodies has recently emerged as a promising approach to the treatment of solid tumors. Programmed death 1 (PD1), which belongs to the CD28 family of proteins, is a T cell surface receptor that regulates T cell activation and proliferation. Its ligand, programmed death-ligand 1 (PD-L1), is frequently expressed in many types of carcinomas \[[@CR11]--[@CR14]\]. Recent clinical trials found that inhibition of the PD-L1-PD1 interaction using specific antibodies resulted in promising antitumor efficacy in patients with various carcinomas \[[@CR15], [@CR16]\]. PD-L1 overexpression in NSCLC was reported ranging from 19 to 100 % \[[@CR17]--[@CR19]\]. Although several studies elucidated the association between common driver genes and PD-L1 expression in NSCLC, the results remain controversial and the prognostic value of PD-L1 expression is unclear \[[@CR20]\].

This study focused on patients with completely resected lung adenocarcinoma and evaluated the association of PD-L1 expression with clinicopathologic parameters and driver genes, as well as its prognosis value in Chinese patients.

Patients and methods {#Sec2}
====================

Patients {#Sec3}
--------

A total of 385 adenocarcinoma patients underwent resection between December 2008 and 2013 in Zhejiang Cancer Hospital. Histological typing was determined according to the 2004 World Health Organization classification \[[@CR21]\]. Tumor-node-metastasis (TNM) staging was based on the 7th edition of the lung cancer staging system. The recurrence or metastases were confirmed using chest CT, brain MRI, and bone scan as well as ultrasound and/or CT of the abdomen. The exclusion criteria included: (1) preoperative chemotherapy or radiation therapy, (2) death from other diseases unrelated to NSCLC. *The Ethics Committee of Zhejiang Cancer Hospital approved this study and written informed consent was obtained from each participant.*

Immunohistochemical analysis of PD-L1 expression {#Sec4}
------------------------------------------------

Immunohistochemical (IHC) staining of PD-L1 expression was performed on 4-6 μm thick formalin-fiated, paraffi-embedded tissue. The concentration of rabbit primary antibody that reacts to PD-L1 The concentration of rabbit primary antibody that reacts to PD-L1 (**Proteintech Group Inc., Chicago, IL, USA**, Catalog number: 66248-1-Ig) was 1:100 in Dako antibody diluent; slides were incubated with this antibody overnight at 4 °C. Then, the slides were incubated with Ventana Omni Mapanti-rabbit secondary antibody for 60 min. AVentana Chromo MapKit was used for antibody detection, and then the slides were counterstained with hematoxylin. Next, the slides were dehydrated and cover slipped as per normal laboratory protocol. Two independent pathologists (Wei Wu and Guoping Cheng) assessed the expressions.

PD-L1 immunostaining results were classified into two groups based on the degree and intensity of staining: (1) negative, when staining was absent or detected in \<5 % of the cells; and (2) positive, when membranous staining was present in ≥5 % of the cells.

We used another antibody (5H1, Cell Signaling Technology, Beverly, MA, USA) to confirmed the PD-L1 expression in 102 patients. The PD-L1 immunostaining criterion is same with the former antibody.

Gene analysis {#Sec5}
-------------

Genomic DNA or RNA was extracted from tumor tissues according to standard protocols (RNeasy Mini Kit, and QiAamp DNA Mini Kit, Qiagen, Hilden, Germany). Briefly, the isolated RNA samples were used for reverse transcription into cDNA using Revert Aid First Strand cDNA Synthesis Kit (Fermentas, St Leon-Rot, Germany). Either genomic DNA or cDNA was used for PCR amplification and sequencing. EGFR, HER2, KRAS, NRAS, BRAF, and PIK3CA were PCR amplified using genomic DNA. Cycle sequencing of the purified PCR products was carried out with PCR primers using the commercially available ADx Mutation Detection Kits (Amory, Xiamen, China).

The ALK, ROS1, and RET fusion mRNA was detected by PCR with fusion gene detection kit (Amory, Xiamen, China). In brief, total RNA was extracted with QiagenRNeasy FFPE Kit. The mRNA was reverse-transcribed to cDNA at 42 °C for 1 h. β-actin was used as the internal control. The RT-PCR conditions were as follows: an initial denaturation at 95 °C for 5 min, followed by 95 °C for 25 s, 64 °C for 20 s, and 72 °C for 20 s to ensure the specificity; and 31 cycles at 93 °C for 25 s, 60 °C for 35 s, 72 °C for 20 s were performed for data collection and sensitivity analysis. All of the positive genes including mutations or fusions were confirmed with Sanger sequencing. All the experiments were performed according to the user manual as described previously \[[@CR22]\].

Statistical analysis {#Sec6}
--------------------

The Chi squared test was used to evaluate the relationships between different driver genes and PD-L1 expression. Survival curves of pathologically confirmed samples were calculated using the Kaplan--Meier method until death or last follow-up. Multivariate analysis was performed using the Cox regression model. Statistical analysis was performed with the SPSS 18 software (Chicago, IL, USA). *P* \< 0.05 was considered statistically significant. The median follow-up was 54 months (6.5--65) and the last follow-up date was July 31, 2015.

Results {#Sec7}
=======

Patient characteristics {#Sec8}
-----------------------

Patients' clinical profile is presented in Table [1](#Tab1){ref-type="table"}. One hundred and ninety-eight patients (51.4 %) were male with a median age of 59 years. One hundred and fifty (39.0 %) patients were former or current smokers. Pathologic stage I was seen in 121 patients, stage II in 79 patients, and stage III in 185 Patients.Table 1Demographic characteristics of the study population (n = 385)NumberGender Male198 Female187Age Range28--79 Median59 \<60207 ≥60178Smoking status Never235 Former/current150Stage I121 II79 III185PD-L1 expression Yes186 No199Gene alteration EGFR205 ALK18 KRAS16 HER29 ROS18 PIK3CA6 RET6 BRAF2 NRAS1 Concurrent alteration24 Pan-negative90Adjuvant treatment Yes269 No116

Gene analysis results {#Sec9}
---------------------

All the patients were analyzed for *EGFR, KRAS, NRAS, PIK3CA, BRAF* and *HER2* mutations and *ALK, ROS1, RET* fusion genes. This analysis included EGFR mutations (n = 205, 53.2 %), followed by *EML4*--*ALK* rearrangements (n = 18, 4.7 %), *KRAS* (n = 16, 4.2 %), *HER2* (n = 9, 2.3 %), *ROS1* (n = 8, 2.1 %), *PIK3CA* (n = 6, 1.6 %), *RET* (n = 6, 1.6 %), *BRAF* (n = 2, 0.5 %), and *NRAS* (n = 1, 0.2 %), and 24 coexisting mutations (6.2 %). All the nine genes were negative in 90 patients, defined as pan-negative. The details of coexisting mutations are listed in Table [2](#Tab2){ref-type="table"}.Table 2Clinical characteristics and PD-L1 expression in concurrent gene alteration patientsCaseGenderAgeStageSmokingGene typePD-L1 expressionOS (month)1Male43IBYesEGFR+PIK3CAYes67+2Female51IIIANoRET+PIK3CAYes423Female58IIIANoEGFR+ALKYes344Male74IANoEGFR+PIK3CANo66+5Male60IIIAYesKRAS+ALKYes35+6Female60IBNoEGFR+RET-M2Yes547Female60IANoEGFR+PIK3CAYes36+8Male64IIANoRET+PIK3CANo559Male69IBNoKRAS6+HER2Yes43+10Male45IIIAYesKRAS+PIK3CAYes2511Female64IIBYesEGFR+HER2No46+12Female75IIIANoEGFR+PIK3CANo24+13Female69IIANoKRAS+PIK3CAYes3614Female49IBNoEGFR+HER2Yes48+15Female55IIBYesROS1+HER2Yes37+16Male62IBYesEGFR+ALKNo4617Male55IIIANoEGFR+PIK3CAYes3918Female68IBNoEGFR+PIK3CAYes58+19Female76IBNoALK+RET-M16No2820Male43IBNoEGFR+PIK3CAYes55+21Male59IIIAYesKRAS+PIK3CAYes18+22Female61IBNoEGFR+PIK3CAYes66+23Female68IIANoEGFR+HER2Yes4524Male62IIIAYesKRAS+HER2Yes16

PD-L1 expression correlated with driver genes {#Sec10}
---------------------------------------------

The PD-L1 membrane expression was detected in 186 of the 385 lung adenocarcinoma patients (48.3 %) (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}). The relationships between clinical parameters or gene characteristics and PD-L1 expression are shown in Table [3](#Tab3){ref-type="table"}. PD-L1 expression was not significantly associated with any clinicopathologic parameters. Patients with PD-L1 positive expression more frequently presented with coexisting mutations (18/24, 75 %), followed by single-gene mutation (145/271, 53.5 %) and pan-negative (23/90, 25.6 %) genes. Differences in PD-L1 expression were found among the coexisting mutations, single-gene mutations and pan-negative genes (*P* \< 0.001).Fig. 1**a** Positive programmed cell death-ligand 1 (PD-L1) immunohistochemical staining in a patient with adenocarcinoma. **b** Negative PD-L1 immunohistochemical staining in another patient with adenocarcinomaFig. 2Relationship between PD-L1 expression and driver genesTable 3Clinical characteristics comparison between PD-L1 positive and negative expression in NSCLC patientsVariablesPD-L1 positive (n = 186)PD-L1 negative (n = 199)*P*Gender0.07 Male87111 Female9988Age0.68 \<60102105 ≥608494Smoking status0.12 Never121114 Former/current6585Pathologic stage0.09 I + II10595 III81104EGFR0.008 Yes11293 No74106ALK0.53 Yes108 No176191KRAS0.16 Yes511 No181188HER20.44 Yes63 No180196ROS10.65 Yes53 No181196PIK3CA0.74 Yes24 No184195RET0.74 Yes33 No183196BRAF0.45 Yes20 No184199NRAS0.97 Yes01 No186198Concurrent alteration0.01 Yes186 No168193Pan-negative\<0.01 Yes2367 No163132

Another antibody (5H1, Cell Signaling Technology, Beverly, MA, USA) was used in 102 patients to detect the PD-L1 expression. The same trend of PD-L1 expression difference existed in patients with different gene abnormality. The PD-L1 positive patitnets was more frequently carried coexisting mutations (5/8, 62.5 %), followed by single-gene positive (32/66, 48.5 %) and pan-negative mutations (10/28, 25.6 %)(*P* = 0.337).

Survival analysis {#Sec11}
-----------------

The median DFS and OS were 48.3 and 58.1 months, respectively. Patients with positive PD-L1 expression had shorter DFS than those with negative PD-L1 expression (38.0 vs. 50.4 months, *P* = 0.014) (Fig. [3](#Fig3){ref-type="fig"}), but the OS between the two groups showed no significant difference (52.9 vs. 68.2 months, *P* = 0.069) (Fig. [4](#Fig4){ref-type="fig"}; Table [4](#Tab4){ref-type="table"}).Fig. 3Disease free survival curves in patients with positive or negative programmed cell death-ligand 1 (PD-L1) staining (38.0 vs. 50.4 months, *P* = 0.014)Fig. 4Overall survival curves in patients with positive or negative programmed cell death-ligand 1 (PD-L1) staining (52.9 vs. 68.2 months, *P* = 0.069)Table 4Univariate analysis for disease-free survival and overall survivalVariablesMedian DFS*P*Median OS*P*Gender0.740.44 Male44.655.6 Female48.959.9Age0.230.39 \<6049.359.3 ≥6042.955.2Smoking status0.160.59 Never49.058.6 Former/current41.356.0Pathologic stage\<0.001\<0.001 I + II52.566.2 III30.245.0Adjuvant treatment0.540.76 Yes49.759.2 No46.556.5Driver genes0.230.24 Positive48.958.7 Negative42.050.4PD-L1 expression0.0140.069 Yes38.052.9 No50.462.0

In univariate analysis, early stage (stage I and II versus III) and PD-L1 expression negative were significantly risk factors for tumor recurrence or metastasis (Figs. [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}), while only early stage was a favorable prognostic factor of OS (Table [4](#Tab4){ref-type="table"}).

In multivariate analysis, only early stage suggested lower risk for DFS, while PD-L1 expression was not correlated with recurrence or metastasis. Early stage was an independent and favorable prognostic factor for OS (Table [5](#Tab5){ref-type="table"}).Table 5Multivariate survival analysis for disease-free survival and overall survivalVariablesDFSOSHR95 % CI*P*HR95 % CI*P*Smoking status (smokers vs. non-smokers)0.840.66--1.070.161.120.81--1.530.48Stage (III vs. I + II)1.711.32--2.210.001.160.84--1.580.00PD-L1 expression (positive vs. negative)1.170.91--1.510.221.791.30--2.460.37

Discussion {#Sec12}
==========

This study shows that PD-L1 is overexpressed in 48.3 % (186/385) of lung adenocarcinoma patients and this overexpression is more frequently seen in patients with coexisting mutations, but less frequently in patients with pan-negative genes. The PD-L1 overexpression is not a prognostic factor for overall survival. To the best of our knowledge, this is the first study with the largest number of patients correlating the nine common driver genes in lung adenocarcinoma and PD-L1 expression.

Several studies have reported the association between *PD*-*L1* expression and driver genes \[[@CR23], [@CR24]\]. The results of the correlation were controversial. Azuma et al. \[[@CR14]\] observed that *PD*-*L1* positive status was significantly associated with *EGFR* mutations . Mu et al. observed no significant correlation between *PD*-*L1* expression and *EGFR*/*ALK* status in stage I NSCLC patients \[[@CR25]\]. Similarly, Zhang et al. found that no association between *PD*-*L1* expression and *EGFR* status in lung adenocarcinoma \[[@CR25]\]. Therefore, the role of inhibition of PD-1/PD-L1 pathway and driver genes based on the results of existing studies is inconclusive, due to several reasons. First, most of the samples in previous studies were relatively small. Second, most of the studies focused on *EGFR* mutations or *ALK* rearrangements, and other driver genes were not well investigated. Last but not least, racial differences may play an important role in the controversial results.

In the present study, PD-L1 overexpression was more frequent in patients with coexisting mutations than in pan-negative patients. One explanation is that the genetic differences affected epigenetics, which may alter the expression of tumor-associated self-antigens, which in turn, affected tumor antigenicity. Increased number of driver genes reflects a higher level of neoantigens, which alters the immune microenvironment and increases the PD-L1 expression \[[@CR26]\].

Because of heterogeneity of tumors, the efficacy of chemotherapy or molecular targeted treatment is relatively limited, combination treatment with different anti-cancer mechanisms drugs hold much potential in this area. Previous studies demonstrated that EGFR and ALK genes could induce PD-L1 expression to facilitate evasion of the host anti-tumour immune response, suggesting an active role for these genes in remodelling the immune microenvironment \[[@CR27], [@CR28]\]. In this way, combination of PD-1/PD-L1 blockade with targeted inhibitor or other drugs may be a promising therapeutic strategy to increase the duration of treatment response and delay development of drug resistance.

The role of PD-L1 in predicting the prognosis of NSCLC was controversial in previous studies \[[@CR20]\]. Some studies found that negative PD-L1 expression led to superior OS in NSCLC patients compared with positive PD-L1 expression \[[@CR14], [@CR29]\], while Yang et al. \[[@CR30]\] concluded that PD-L1 expression had no significant correlation with OS. In the present cohort, we found no association between the PD-L1 expression and overall survival in NSCLC patients. However, PD-L1 expression was related to shorter DFS. The results may contribute to the treatment after recurrence or metastasis.

Our study limitations are as follows. One major limitation was its retrospective nature. Second, only 24 patients with coexisting mutations were included, and the small sample size may influence the results of the current study. Third, different antibodies were used in different anti-PD-1 or PD-L1 therapies in clinical trials currently. The choice of antibody and the threshold for positivity might influence the results of different studies. Only one antibody and 5 % threshold were used in the present study. Different anti-PD-L1 antibodies may need to be validated in the same sample in future studies.

Conclusions {#Sec13}
===========

In conclusion, we demonstrated the expression of PD-L1 in over 48 % of lung adenocarcinoma patients and the expression was associated with coexisting driver genes. PD-L1 expression is not associated with overall survival in patients with completely resected NSCLC.
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